|
Marknaden stängd -
Andra börsplatser
|
5-dagars förändring | Förändring 1 jan. | ||
| 399,70 DKK | −2,20 % |
|
−1,87 % | −14,30 % |
| 02-13 | Dagbok – Europas STOXX 600: Kommande rapportvecka för bolagsvinster | RE |
| 02-09 | DNB Carnegie sänker riktkursen för Zealand Pharma till 595 danska kronor (610), upprepar köp | FW |
| Skatteperiod: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Lönsamhet | ||||||||||
Return on Assets | −30,08 | −34,28 | −28,21 | −19,93 | −13,81 | |||||
Return on Total Capital | −37,62 | −42,7 | −33,31 | −22,99 | −14,8 | |||||
Return On Equity % | −68,51 | −94,4 | −110,75 | −58,43 | −21,13 | |||||
Return on Common Equity | −68,51 | −94,4 | −110,75 | −58,43 | −21,13 | |||||
Marginalanalys | ||||||||||
Gross Profit Margin % | 74,37 | 59,39 | 100 | 99,07 | 87,44 | |||||
SG&A Margin | 132,51 | 217,47 | 259,18 | 62,99 | 644,47 | |||||
EBITDA Margin % | −224,3 | −350,07 | −698,78 | −161,83 | −2,01 tn | |||||
EBITA Margin % | −227,01 | −356,27 | −782,86 | −163,73 | −2,02 tn | |||||
EBIT Margin % | −228,95 | −358,96 | −782,86 | −163,73 | −2,02 tn | |||||
Income From Continuing Operations Margin % | −239,65 | −348,01 | −928,6 | −205,3 | −1,72 tn | |||||
Net Income Margin % | −239,65 | −348,01 | −1,16 tn | −205,3 | −1,72 tn | |||||
Net Avail. For Common Margin % | −239,65 | −348,01 | −928,6 | −205,3 | −1,72 tn | |||||
Normalized Net Income Margin | −151,25 | −217,56 | −498,09 | −100,91 | −1,13 tn | |||||
Levered Free Cash Flow Margin | −122,79 | −253,28 | −367,48 | −66,8 | −1,17 tn | |||||
Unlevered Free Cash Flow Margin | −122,27 | −252,4 | −334,03 | −62,37 | −1,16 tn | |||||
Tillgångsomslutning | ||||||||||
Asset Turnover | 0,21 | 0,15 | 0,06 | 0,19 | 0,01 | |||||
Fixed Assets Turnover | 2,09 | 1,35 | 0,54 | 2,17 | 0,46 | |||||
Receivables Turnover (Average Receivables) | 14,96 | 4,9 | 0,77 | 2,88 | 0,43 | |||||
Inventory Turnover (Average Inventory) | - | 1,3 | - | 0,69 | 0,85 | |||||
Kortfristig likviditet | ||||||||||
Current Ratio | 4 | 5,15 | 6,73 | 6,25 | 21,14 | |||||
Quick Ratio | 3,71 | 4,6 | 6,73 | 6,23 | 21,11 | |||||
Operating Cash Flow to Current Liabilities | −1,94 | −3,63 | −4,82 | −1,5 | −2,31 | |||||
Days Sales Outstanding (Average Receivables) | 24,47 | 74,55 | 472,24 | 126,7 | 850,51 | |||||
Days Outstanding Inventory (Average Inventory) | - | 281,82 | - | 526,71 | 433,05 | |||||
Average Days Payable Outstanding | - | 143 | - | 5,05 tn | 4,69 tn | |||||
Cash Conversion Cycle (Average Days) | - | 213,37 | - | −4,4 tn | −3,41 tn | |||||
Långsiktig solvens | ||||||||||
Total Debt/Equity | 10,58 | 84,87 | 64,23 | 7,49 | 4,55 | |||||
Total Debt / Total Capital | 9,57 | 45,91 | 39,11 | 6,96 | 4,35 | |||||
LT Debt/Equity | 9,44 | 83,26 | 62,43 | 6,44 | 4,36 | |||||
Long-Term Debt / Total Capital | 8,54 | 45,04 | 38,01 | 5,99 | 4,17 | |||||
Total Liabilities / Total Assets | 30,23 | 55,13 | 47,01 | 19,55 | 9,35 | |||||
EBIT / Interest Expense | −279,42 | −256,71 | −14,09 | −21,73 | −37,27 | |||||
EBITDA / Interest Expense | −269,07 | −246,87 | −12,32 | −20,95 | −36,6 | |||||
(EBITDA - Capex) / Interest Expense | −277,72 | −252,28 | −12,53 | −21,38 | −36,89 | |||||
Total Debt / EBITDA | −0,17 | −0,78 | −0,74 | −0,22 | −0,31 | |||||
Net Debt / EBITDA | 1,45 | 0,63 | 0,92 | 2,8 | 6,95 | |||||
Total Debt / (EBITDA - Capex) | −0,16 | −0,76 | −0,72 | −0,22 | −0,31 | |||||
Net Debt / (EBITDA - Capex) | 1,4 | 0,62 | 0,9 | 2,74 | 6,89 | |||||
Tillväxt jämfört med föregående år | ||||||||||
Total Revenues, 1 Yr. Growth % | 754,8 | −17,19 | −4,2 | 229,65 | −81,71 | |||||
Gross Profit, 1 Yr. Growth % | 542,14 | −33,87 | 6,57 | 226,58 | −83,86 | |||||
EBITDA, 1 Yr. Growth % | 35,91 | 29,24 | −5,46 | −23,96 | 126,88 | |||||
EBITA, 1 Yr. Growth % | 36,42 | 29,96 | 4,08 | −31,27 | 126,12 | |||||
EBIT, 1 Yr. Growth % | 37,59 | 29,83 | 4,08 | −31,27 | 126,12 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 48,15 | 20,24 | 27,91 | −27,12 | 53,3 | |||||
Net Income, 1 Yr. Growth % | 48,15 | 20,24 | 18,07 | −41,46 | 53,3 | |||||
Normalized Net Income, 1 Yr. Growth % | 47,54 | 19,1 | 10,03 | −33,42 | 104,65 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 30,51 | 7,61 | 18,68 | −40,5 | 30,58 | |||||
Accounts Receivable, 1 Yr. Growth % | 6,09 tn | 57,1 | −24,65 | 5,83 | 97,91 | |||||
Inventory, 1 Yr. Growth % | - | 82,1 | −98,91 | 517,03 | 34,82 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 69,97 | 3,95 | −25,27 | −9,45 | −16,42 | |||||
Total Assets, 1 Yr. Growth % | 10,16 | 17,35 | −25,53 | 28,59 | 380,08 | |||||
Tangible Book Value, 1 Yr. Growth % | −5,51 | −25,41 | −6,65 | 93,72 | 444,36 | |||||
Common Equity, 1 Yr. Growth % | −1,08 | −24,53 | −12,06 | 95,22 | 440,97 | |||||
Cash From Operations, 1 Yr. Growth % | 68,2 | 75,98 | −22,26 | −54,83 | 118,67 | |||||
Capital Expenditures, 1 Yr. Growth % | 19,05 | −11,62 | −47,09 | −4,01 | −10,57 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 36,6 | 70,81 | −35,2 | −40,38 | 221,6 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 36,9 | 70,93 | −40,84 | −38,8 | 240,95 | |||||
Sammansatt Årlig Tillväxthastighet Över Två År | ||||||||||
Total Revenues, 2 Yr. CAGR % | 205,01 | 166,05 | −26,41 | 77,71 | −22,35 | |||||
Gross Profit, 2 Yr. CAGR % | 175,49 | 106,07 | −26,41 | 86,56 | −27,39 | |||||
EBITDA, 2 Yr. CAGR % | 33,9 | 33,55 | 11,59 | −15,04 | 31,34 | |||||
EBITA, 2 Yr. CAGR % | 34,03 | 33,15 | 14,02 | −15,29 | 24,66 | |||||
EBIT, 2 Yr. CAGR % | 34,6 | 33,65 | 14,02 | −15,29 | 24,66 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 20,69 | 33,47 | 20,17 | −3,45 | 5,7 | |||||
Net Income, 2 Yr. CAGR % | 20,69 | 33,47 | 19,15 | −16,86 | −5,27 | |||||
Normalized Net Income, 2 Yr. CAGR % | 34,65 | 32,56 | 10,92 | −14,28 | 16,73 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 7,95 | 18,51 | 9,51 | −15,97 | −11,85 | |||||
Accounts Receivable, 2 Yr. CAGR % | 276,8 | 886,09 | 57,71 | −10,7 | 29,39 | |||||
Inventory, 2 Yr. CAGR % | - | - | −85,94 | −74,12 | 188,42 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 269,19 | 32,92 | −11,86 | −17,74 | −13 | |||||
Total Assets, 2 Yr. CAGR % | 19,7 | 13,7 | −6,52 | −2,14 | 148,46 | |||||
Tangible Book Value, 2 Yr. CAGR % | 2,46 | −16,05 | −16,56 | 34,48 | 224,74 | |||||
Common Equity, 2 Yr. CAGR % | 4,94 | −13,59 | −18,53 | 31,03 | 224,98 | |||||
Cash From Operations, 2 Yr. CAGR % | 22,17 | 72,05 | 16,96 | −40,74 | −0,61 | |||||
Capital Expenditures, 2 Yr. CAGR % | 149,04 | 2,57 | −31,62 | −28,73 | −7,34 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | −35,98 | 52,75 | 5,63 | −37,69 | 38,47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | −36,19 | 52,97 | 5,57 | −39,66 | 44,46 | |||||
Treårig Sammansatt Årlig Tillväxthastighet | ||||||||||
Total Revenues, 3 Yr. CAGR % | 37,36 | 97,5 | 36,01 | 21,31 | −16,72 | |||||
Gross Profit, 3 Yr. CAGR % | 29,08 | 71,21 | 36,46 | 20,93 | −17,49 | |||||
EBITDA, 3 Yr. CAGR % | 48,14 | 32,33 | 8,16 | −1,67 | 17,87 | |||||
EBITA, 3 Yr. CAGR % | 47,78 | 32,66 | 11,46 | −3,59 | 17,51 | |||||
EBIT, 3 Yr. CAGR % | 48,2 | 32,99 | 11,46 | −3,59 | 17,51 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 45,58 | 20,54 | 19,1 | 1,72 | 12,64 | |||||
Net Income, 3 Yr. CAGR % | 45,58 | 20,54 | 28,13 | −5,98 | 1,95 | |||||
Normalized Net Income, 3 Yr. CAGR % | 45,08 | 29,26 | 12,66 | −6,34 | 14,57 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 30,85 | 7,84 | 7,32 | −10,64 | −2,67 | |||||
Accounts Receivable, 3 Yr. CAGR % | 101,53 | 181,49 | 435,96 | 38,07 | 8,05 | |||||
Inventory, 3 Yr. CAGR % | - | - | - | −50,4 | −55,13 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 136,47 | 141,98 | 9,7 | −11,07 | −17,3 | |||||
Total Assets, 3 Yr. CAGR % | 34,68 | 18,91 | −1,26 | 3,97 | 66,28 | |||||
Tangible Book Value, 3 Yr. CAGR % | 31,56 | −7,83 | −13,03 | 10,49 | 114,32 | |||||
Common Equity, 3 Yr. CAGR % | 33,67 | −5,98 | −13,08 | 9,02 | 110,2 | |||||
Cash From Operations, 3 Yr. CAGR % | 35,19 | 37,97 | 32,02 | −14,82 | −8,42 | |||||
Capital Expenditures, 3 Yr. CAGR % | 51,33 | 76,32 | −17,74 | −23,43 | −23,13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 47,56 | −11,21 | 6,36 | −12,56 | 7,68 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 51,05 | −11,38 | 3,25 | −11,81 | 7,47 | |||||
Sammansatt Årlig Tillväxthastighet Över Fem År | ||||||||||
Total Revenues, 5 Yr. CAGR % | 13,49 | 4,85 | −5,27 | 55,27 | 8,69 | |||||
Gross Profit, 5 Yr. CAGR % | 9,7 | −2,77 | −3,17 | 57,88 | 6,02 | |||||
EBITDA, 5 Yr. CAGR % | 60,2 | 55,23 | 24,41 | 4,65 | 16,99 | |||||
EBITA, 5 Yr. CAGR % | 58,05 | 54,34 | 26,78 | 4,68 | 16,64 | |||||
EBIT, 5 Yr. CAGR % | 58,32 | 54,57 | 26,78 | 4,68 | 16,64 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 49,35 | 45,28 | 28,61 | 3,9 | 13,55 | |||||
Net Income, 5 Yr. CAGR % | 49,35 | 45,28 | 34,37 | 3,9 | 13,55 | |||||
Normalized Net Income, 5 Yr. CAGR % | 48,14 | 44,3 | 24,24 | 3,25 | 14,34 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 34,88 | 29,7 | 16,23 | −8,07 | −0,81 | |||||
Accounts Receivable, 5 Yr. CAGR % | −21,72 | 44,7 | 82,71 | 106,31 | 203,55 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 66,89 | 74,61 | 59,34 | 57,16 | −0,01 | |||||
Total Assets, 5 Yr. CAGR % | 22,6 | 24,38 | 16,38 | 9,99 | 42,82 | |||||
Tangible Book Value, 5 Yr. CAGR % | 35,96 | 25,73 | 9,65 | 7,2 | 47,31 | |||||
Common Equity, 5 Yr. CAGR % | 37,27 | 27,24 | 9,65 | 7,37 | 47,3 | |||||
Cash From Operations, 5 Yr. CAGR % | 25,1 | 96,95 | 27,58 | −1,6 | 17,85 | |||||
Capital Expenditures, 5 Yr. CAGR % | 44,03 | 53,47 | 10,14 | 22,72 | −13,73 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 18,11 | 50,55 | 23,13 | −26,38 | 18,32 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 20,2 | 45,63 | 22,61 | −27,42 | 18,23 |
- Börsen
- Aktier
- ZEAL Aktie
- Finanser Zealand Pharma A/S
- Finansiella nyckeltal
Välj din utgåva
All finansiell information anpassad till den nationella nivån
MarketScreener is also available in this country: United States.
Switch edition















